DUET-2: Week 48 results of a Phase III randomized double-blind trial to evaluate the efficacy and safety of etravirine (ETR; TMC125) versus placebo in 591 treatment-experienced HIV-1-infected patients

VL reduction from baseline

Margaret Johnson,¹ Thomas Campbell,² Bonaventura Clotet,³ Christine Katlama,⁴ Adriano Lazzarin,⁵ William Towner,⁶ Monika Peeters,⁷ Johan Vingerhoets,⁷ Stijn Bollen,⁷ Goedele De Smedt⁷ on behalf of the DUET-2 study group

¹Royal Free Hospital, London, UK; ²University of Colorado Health Sciences Center, Denver, CO, USA; ³Hospital Universitari Germans Trias i Pujol and IrsiCaixa Foundation, Barcelona, Spain; 4Hôpital Pitié-Salpêtrière, Paris, France; San Raffaele University, Milan, Italy; Kaiser Permanente, Los Angeles, CA, USA; Tibotec BVBA, Mechelen, Belgium

Abstract

Background

The Week 24 primary analysis of DUET-2 showed that ETR, a nextgeneration NNRTI, provides strong antiviral activity and a good tolerability profile in treatment-experienced patients with HIV-1. We present a pre-planned analysis of Week 48 efficacy and safety data.

Methods

DUET-2 is an ongoing 96-week randomized double-blind Phase III trial designed to show superiority of ETR 200mg vs placebo, both given twice daily (bid) with a background regimen (BR) of darunavir/r, investigator-selected NRTI(s) and optional enfuvirtide (ENF), in patients with documented NNRTI resistance and \geq 3 primary protease inhibitor (PI) mutations (November 2005 IAS-USA list). The primary endpoint was the percentage of patients with a confirmed viral load (VL) of <50 copies/mL at Week 24 (time to loss of virologic response; TLOVR). Safety was also assessed throughout the study.


		Week 24		Week 48		
	ETR + BR	Placebo + BR	Difference (95% CI)	ETR + BR	Placebo + BR	Difference (95% CI)
VL <50 copies/mL, %	63	42	21 (13; 29) p<0.0001*	61	41	21 (13; 28) p<0.0001*
VL <400 copies/mL, %	75	53	22 (14; 29) p<0.0001*	72	48	24 (16; 32) p<0.0001*
Mean (SE) change in VL, log10 copies/mL	-2.4 (0.08)	-1.7 (0.08)	-0.51 [±] (0.27; 0.74) p<0.0001**	-2.2 (0.08)	-1.5 (0.08)	-0.64 [±] (0.39; 0.89) p<0.0001**
Mean (SE) change in CD4 cell count, cells/mm³	78 (4.9)	66 (4.7)	6.5 ⁺ (–7.8; 20.9) p=0.3809**	94 (5.9)	72 (6.4)	20.8 [±] (3.9; 37.8) p=0.0160**


SF = standard error


Results

The intent-to-treat (ITT) population included 591 patients (median baseline VL was 4.8 log₁₀ copies/mL; median CD4 cell count was 105 cells/mm³, 55% patients were CDC Category C, median number of NNRTI mutations was two, 27% of patients used enfuvirtide de novo).

Of patients with a VL of <50 copies/mL at Week 24, 90% of patients maintained a VL of <50 copies/mL at Week 48 with ETR + BR vs 88% with placebo + BR. Furthermore, a significantly increased mean CD4 cell count was observed at Week 48 with ETR + BR vs placebo + BR. Similar to Week 24, Week 48 safety data showed that the incidence and severity of adverse events (AEs) with ETR were similar to placebo: any AE (96% ETR vs 95% placebo), serious AEs (21% vs 22%), grade 3/4 AEs (38% vs 34%). AEs leading to discontinuation (8% vs 4%). The most common AEs were diarrhea (22% vs 23%). rash (any type) (17% vs 11%) and nausea (15% vs 11%). Most rashes were mild to moderate, infrequently led to discontinuation (2.4% vs 0%), occurred early and resolved with continued treatment. The incidences of nervous system (17% vs 18%) and psychiatric disorders (20% vs 21%) with ETR were comparable to placebo.







- in DUET-2 one case of SJS was observed in the placebo group and was likely related to an allergic reaction to trimethoprim/sulfamethoxazole Infrequently lead to discontinuation
- 2.4% of patients permanently discontinued
- nost rashes were self-limiting with continued treatment In DUET-2, incidence of rash was similar in men and women, with no clear differences in severity or treatment discontinuations according to gender No increased risk in patients with a history of NNRTI-related rash

*Fisher's exact test: SJS = Stevens Johnson Syndrom

Grade 3 and 4 treatment-emergent laboratory abnormalities at Week 48

	DU	ET-2	Pooled DUE1	-1 and
arameter, %	ETR + BR (n=295)	Placebo + BR (n=296)	ETR + BR (n=599)	Place (n
least one laboratory abnormality				
rade 3	38	35	36	
rade 4	9	8	10	
ost common grade 3/4 laboratory normalities [‡]				
DL-cholesterol	10	8	7	
otal cholesterol	9	5	8	
riglycerides	9	6	9	
ancreatic amylase	8	9	9	
Decreased neutrophils	5	6	5	
	*Realed DI IET dat	a included for compa	ringer fußlig in ET	Parous
	Pooled DUET dat	a included for compa	LDL = lo	

Supported by Tibotec

Margaret Johnson, MD Royal Free Hospital London UK Phone: +44 20783 02775 margaret.johnson@royalfree nhs.uk

Response (<50 copies/mL) by PSS (DRV FC <40)* at Week 48						
DUET-2	Pooled DUET-1 and DUET-2 [‡]					
ETR + BR (n=295)	ETR + BR (n=599)					
Placebo + BR (n=296)	Placebo + BR (n=604)					
15 33%	면 <u>12/36</u> 33%					
18 0%	0 0/35 0%					
	0 1226 33% 0/35 0% 0/35 0%					

%	82%	
80 bies/ml		100

DUET-2*	
acebo + BR (n=604)	
96	
35	
6	
23	
3	
11	
24	
13	
13	
20	
20	
6	





5% in ETR group in either trial LDL = low-density lipoprotein

DUET-2: Conclusions

- At 48 weeks, in treatment-experienced patients, ETR provided durable and superior virologic and immunologic benefits over placebo
- in DUET-2 61% of patients achieved undetectable VL
- (<50 copies/mL) compared with 41% in the placebo group • in the pooled analysis, 61% of patients achieved
- undetectable VL (<50 copies/mL) compared with 40% in the placebo group
- a statistically significant greater number of patients who received ETR achieved an undetectable VL (<50 copies/mL) than those who received placebo, irrespective of previous ENF use
- Virologic and immunologic responses were well maintained from 24 to 48 weeks
- of the patients achieving undetectable VL (<50 copies/mL) with ETR plus BR at Week 24, 90% had maintained virologic suppression at Week 48
- ETR was well tolerated in patients over 48 weeks - with the exception of rash, incidence and severity of AEs with
- ETR were similar to placebo
- ETR provides a new effective and well-tolerated treatment option for treatment-experienced patients

Reference

1. Tambuyzer L, et al. EHDRW 2007. Abstract 67

Acknowledgments

• We express our gratitude to the patients that participated in the study, as well as the study center staff, DSMB, clinical event adjudication panel, Virco, Tibotec personnel, data and safety monitoring board and the following principal investigators

Australia: J Chuah, D Cooper, B Eu, J Hoy, C Workman

Belgium: N Clumeck, R Colebunders, M Moutschen

Canada: J Gill, K Gough, P Junod, D Kilby, J Montaner, A Rachlis, B Trottier, CM Tsoukas

France: C Arvieux, L Cotte, JF Delfraissy, PM Girard, B Marchou, JM Molina, D Vittecog Y Yazdannanah P Yeni

Germany: K Arasteh S Esser G Fätkenheuer H Gellermann K Göbels FD Goebel, H Jäger, A Moll, JK Rockstroh, D Schuster, S Staszewski, A Stoehr Italy: A Antinori, G Carosi, G Di Perri, R Esposito, F Mazzotta, G Pagano, E Raise, S Rusconi, L Sighinolfi, F Suter

The Netherlands: PHJ Frissen, JM Prins, BJA Rijnders

- Poland: A Horban
- Portugal: F Antunes, M Miranda, J Vera

Spain: P Domingo, G Garcia, JM Gatell, J González-Lahoz, J López-Aldeguer, D Podzamczer

UK: P Easterbrook, M Fisher, C Orkin, E Wilkins

USA: B Barnett, J Baxter, G Beatty, D Berger, C Borkert, C Cohen, M Conant, J Ernst, C Farthing, T File, M Frank, JE Gallant, AE Greenberg, C Hicks, DT Jayaweera, S Kerkar, N Markowitz, C Martorell, C McDonald, D McMahon, M Mogyoros, RA Myers Jr, G Richmond, K Sathasivam, S Schneider, H Schrager, P Shalit, FP Siegal, L Sloan, K Smith, S Smith, P Tebas, LS Tkatch